7 Or 8 Amino Acid Residues In The Peptide Chain Patents (Class 514/21.7)
  • Patent number: 10683326
    Abstract: Disclosed are various crystalline salt forms of D-Arg-Dmt-Lys-Phe-NH2.
    Type: Grant
    Filed: March 10, 2017
    Date of Patent: June 16, 2020
    Assignee: Stealth BioTherapeutics Corp.
    Inventors: Scott M. Duncan, Martin P. Redmon
  • Patent number: 10631616
    Abstract: A sheet pack comprising an absorbent layer impregnated with a treatment composition containing at least one ingredient that when topically applied to skin stimulates a gene that is variably expressed over a 24 hour period in native untreated skin cells; the sheet pack contained in a package with user instructions to topically apply the sheet pack to the skin at a time when the gene that is stimulated by the ingredient is being maximally expressed in native untreated skin cells; and methods for treating skin and methods for making a sheet pack.
    Type: Grant
    Filed: November 15, 2017
    Date of Patent: April 28, 2020
    Assignee: ELC Management LLC
    Inventors: Anne Carullo, Jennifer Palmer Quintano, Joyce Kassouf, Nadine Pernodet, Donald Collins, Dawn Layman, Allan Hafkin, Osvaldo Fontanet
  • Patent number: 10183055
    Abstract: The present invention provides oligopeptides, in particular, Ang-(1-7) derivatives, and methods for using and producing the same. In one particular embodiment, oligopeptides of the invention have higher blood-brain barrier penetration and/or in vivo half-life compared to the native Ang-(1-7), thereby allowing oligopeptides of the invention to be used in a wide variety of clinical applications including in treatment of cognitive dysfunction and/or impairment, pain, and traumatic brain injury.
    Type: Grant
    Filed: January 9, 2017
    Date of Patent: January 22, 2019
    Assignee: ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA
    Inventors: Meredith Hay, John Konhilas, Robin L. Polt, Todd Vanderah, Brittany Forte, Tally Milnes, Evan Jones, Lajos Szabo
  • Patent number: 10028999
    Abstract: The present invention is directed to a peptide conjugate comprising an alpha-amino protecting moiety, a peptide comprising the amino acid sequence at least 3 amino-acid long derived from the C?-terminus of PAR-1, or an active variant thereof and a protease-disabling moiety. The present invention is further directed to pharmaceutical compositions comprising the peptide conjugate and use thereof for treating diseases and disorder associated with excessive PAR-1 activity.
    Type: Grant
    Filed: May 11, 2015
    Date of Patent: July 24, 2018
    Assignee: TEL HASHOMER MEDICAL RESEARCH INFRASTRUCTURE AND SERVICES LTD.
    Inventors: Joab Chapman, Efrat Shavit-Stein
  • Patent number: 10022314
    Abstract: Compositions of the invention comprise 8-oxoguanine glycosylase (OGG1) and SIRT6 activating peptide G-A-G-V-S-A-E-NH2. Compositions of the invention exhibit anti-aging effects by promoting the repair of skin cell DNA and/or by protecting skin cell DNA from UV damage.
    Type: Grant
    Filed: November 30, 2016
    Date of Patent: July 17, 2018
    Assignee: ELC MANAGEMENT LLC
    Inventors: Nadine Pernodet, Kelly Dong, Edward Pelle
  • Patent number: 9987330
    Abstract: Disclosed is a method of treating, reducing, or preventing pruritis in a mammal, the method comprising administering at least one natriuretic polypeptide b (Nppb) blocking agent to a mammal in an amount effective to treat or prevent pruritis in the mammal. An in vitro method of identifying a compound that inhibits Nppb activity is also disclosed.
    Type: Grant
    Filed: December 4, 2014
    Date of Patent: June 5, 2018
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Mark A. Hoon, Santosh K. Mishra
  • Patent number: 9914775
    Abstract: Methods for identifying compounds that positively regulate connexin 43 hemichannels.
    Type: Grant
    Filed: August 21, 2014
    Date of Patent: March 13, 2018
    Assignee: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Jean X. Jiang, Manuel A. Riquelme, Sumin Gu
  • Patent number: 9279807
    Abstract: The present invention provides materials and methods for the treatment of celiac disease. In addition, the present invention provides materials and methods of monitoring the treatment of a subject having celiac disease.
    Type: Grant
    Filed: August 22, 2011
    Date of Patent: March 8, 2016
    Assignees: ALBA THERAPEUTICS CORPORATION, UNIVERSITY OF MARYLAND, BALTIMORE
    Inventors: Alessio Fasano, Blake Paterson
  • Patent number: 9220744
    Abstract: This invention relates to compositions and methods for treatment of vascular conditions. The invention provides arginine polymers and arginine homopolymers for the treatment and/or prevention of glaucoma, pulmonary hypertension, asthma, chronic obstructive pulmonary disease, erectile dysfunction, Raynaud's syndrome, heparin overdose, vulvodynia, and wound healing. The invention also provides arginine polymers and arginine homopolymers for use in organ perfusate and preservation solutions.
    Type: Grant
    Filed: January 11, 2014
    Date of Patent: December 29, 2015
    Assignee: Lumen Therapeutics, LLC
    Inventors: Jonathan B. Rothbard, Paul L. McGrane, Edgar G. Engleman, C. Garrison Fathman, Erik Kreider
  • Patent number: 9187526
    Abstract: Peptides derived from cancer specific isoform of proliferating cell nuclear antigen (caPCNA, also known as csPCNA) or from nmPCNA-interacting proteins interfere with intracellular protein-protein interaction, thereby causing a reduction in the proliferative potential of cancer. These peptides serve as therapeutic compositions to reduce the proliferation of cancer cells and also augment existing chemotherapeutic methods.
    Type: Grant
    Filed: February 18, 2014
    Date of Patent: November 17, 2015
    Inventors: Robert J. Hickey, Linda H. Malkas
  • Publication number: 20150148295
    Abstract: Described herein are methods and compositions for modulating the release and/or drug loading characteristics of encapsulated bioactive agents in polymer-based delivery systems via direct modification of the isoelectric point and/or net charge of the bioactive agent.
    Type: Application
    Filed: February 9, 2015
    Publication date: May 28, 2015
    Inventors: Kevin Burton, Torsten Woehr, Thomas R. Tice, Mimoun Ayoub
  • Publication number: 20150140093
    Abstract: Compositions, methods of making, and methods of using nanoclusters in which the nanoclusters comprise a plurality of nanoparticles having a core of nanoparticles arranged such that the surfaces of the nanoparticles contact adjacent nanoparticles, the nanoparticles comprise an active ingredient, and the nanocluster has a mass median aerodynamic diameter of from about 0.25 ?m to about 20 ?m.
    Type: Application
    Filed: November 6, 2014
    Publication date: May 21, 2015
    Inventors: Cory J. Berkland, Lianjun Shi, Nashwa El Gendy, Carl Plumley, Mark Bailey
  • Publication number: 20150140046
    Abstract: Compounds of general formula (I): R1-Wn-Xm-AA1-AA2-AA3-AA4-AA5-AA6-AA7-AA8-AA9-Yp-Zq-R2 (I) their stereoisomers, mixtures thereof and/or their cosmetically or pharmaceutically acceptable salts, preparation processes, cosmetic or pharmaceutical compositions which contain them and their use in medicine, particularly in the treatment and/or prevention of pain, inflammation, itching, neurological, compulsive and/or neuropsychiatric diseases and/or disorders and in processes of treatment and/or care of the skin, hair and/or mucous membranes mediated by neuronal exocytosis.
    Type: Application
    Filed: April 12, 2013
    Publication date: May 21, 2015
    Inventors: Antonio Vicente Ferrer Montiel, Gregorio Fernández Ballester, José María García Antón, Cristina Carreño Serraïma, Núria Almiñana Doménech, Raquel Delgado González
  • Publication number: 20150140060
    Abstract: Provided herein are compositions and methods for use in promoting wound healing and tissue regeneration following tissue injury in a subject.
    Type: Application
    Filed: November 14, 2014
    Publication date: May 21, 2015
    Inventor: Gautam GHATNEKAR
  • Patent number: 9034824
    Abstract: Potent compounds having combined antioxidant, anti-inflammatory, anti-radiation and metal chelating properties are described. Short peptides having these properties, and methods and uses of such short peptides in clinical and cosmetic applications are described.
    Type: Grant
    Filed: July 3, 2014
    Date of Patent: May 19, 2015
    Assignees: ONEDAY—BIOTECH AND PHARMA LTD., YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD.
    Inventors: Josef Mograbi, Daphne Atlas, Shoshana Keynan
  • Patent number: 9029327
    Abstract: Vaccine comprising a peptide bound to a pharmaceutically acceptable carrier, said peptide having the amino acid sequence (Formula?I) (SEQ?ID?NO:?1) (X1)m(X2)n(X3)oX4X5HPX6, for treating and/or preventing a physical disorder associated with the renin-activated angiotensin system, wherein X1 is G or D, X2 is A, P, M, G, or R, X3 is G, A, H, or V, X4 is S, A, D, or Y, X5 is A, D, H, S, N, or I, X6 is A, L or F, wherein m, n and o are independently 0 or 1 under the premise that when o is 0 m and n are 0 and when n is 0 m is 0, and wherein the peptide is not DRVYIHPF (SEQ ID NO:4).
    Type: Grant
    Filed: July 23, 2010
    Date of Patent: May 12, 2015
    Assignee: Affiris AG
    Inventors: Günther Staffler, Petra Lührs, Andreas Mairhofer, Frank Mattner, Walter Schmidt, Andrea Dolischka
  • Publication number: 20150126457
    Abstract: A therapeutic composition for treating brain injury comprising a polyarginine peptide of from 5 to 9 arginines, and further comprising 1 or more terminal cysteines. The composition is administered in therapeutically effective dosages prophylactic ally as soon as possible post-injury in treating neuronal injury.
    Type: Application
    Filed: April 17, 2013
    Publication date: May 7, 2015
    Inventors: Dennis J. Goebel, John Marshall
  • Publication number: 20150125522
    Abstract: Bioavailability of peptide active agents to be administered orally is enhanced by a pharmaceutical composition providing targeted release of the peptide to the intestine by combining the composition with an absorption enhancer. Bioavailability is further significantly increased by administering the composition in an acid-resistant protective vehicle which transports components of the invention through the stomach. The composition may optionally further include a sufficient amount of a pH-lowering agent to lower local intestinal pH. All components are released together into the intestine with the peptide.
    Type: Application
    Filed: September 12, 2014
    Publication date: May 7, 2015
    Inventors: Nozer M. Mehta, William Stern, James P. Gilligan
  • Publication number: 20150125392
    Abstract: AV?6 peptide ligands, functional variants thereof and their nucleic acids encoding them are disclosed with their uses in the treatment and imaging of AV?6 mediated diseases.
    Type: Application
    Filed: December 11, 2014
    Publication date: May 7, 2015
    Inventors: Mark J. Howard, Danielle Dicara, John Marshall
  • Publication number: 20150119341
    Abstract: Melanocortin receptor-specific linear peptides of the formula where R1, R2, R3, R4, R5, R6, R7, R8, R9 and R10 are as defined in the specification, compositions and formulations including peptides of the foregoing formula or salts thereof, and pharmaceutical compositions for preventing, ameliorating or treating melanocortin-1 receptor-mediated or responsive diseases, indications, conditions and syndromes.
    Type: Application
    Filed: December 30, 2014
    Publication date: April 30, 2015
    Inventors: Wei Yang, Yi-Qun Shi
  • Publication number: 20150119340
    Abstract: A fusion peptide including a hydrophobic peptide and a basic peptide, a pharmaceutical composition including the fusion peptide, a cell membrane penetrating conjugate including the fusion peptide and a substance of interest, and a method for intracellular delivery of a substance of interest using the fusion peptide.
    Type: Application
    Filed: October 29, 2014
    Publication date: April 30, 2015
    Inventors: Jung Min Kim, Kyoung Hu Lee, Jae Il Lee, Jungmin Lee
  • Publication number: 20150118315
    Abstract: A finished pharmaceutical product adapted for oral delivery of an aromatic-cationic peptide, wherein the product comprises a therapeutically effective amount of the peptide; at least one pharmaceutically acceptable pH-lowering agent; and at least one absorption enhancer effective to promote bioavailability of the active agent. The product is adapted for use in a method for enhancing the bioavailability of a therapeutic aromatic-cationic peptide delivered orally.
    Type: Application
    Filed: June 13, 2012
    Publication date: April 30, 2015
    Applicant: Stealth Peptides International, Inc.
    Inventor: D. Travis Wilson
  • Publication number: 20150111837
    Abstract: The invention relates to the field of biochemistry and concerns of recombinant method for production of peptides and the resulting peptides. In particular, the invention relates to peptides with the following general formula: A-Thr-Lys-Pro-B-C-D-X, where: A—0, Met, Met (O), Thr, Ala, His, Phe, Lys, Gly B—0, Gly, Asp, Trp, Gin, Asn, Tyr, Pro, Arg C—0, Arg, Phe, Tyr, Gly, His, Pro, Lys D—0, Val, Gly, Tyr, Trp, Phe, His X—OH, OCH3, NH2, where 0 is no amino acid residue, provided that if A?0, then B and/or C and/or D?0, if B?0, then C and/or D?0, excluding the peptides Phe-Thr-Lys-Pro-Gly, Thr-Lys-Pro-Pro-Arg, Thr-Lys-Pro-Arg-Gly.
    Type: Application
    Filed: May 28, 2013
    Publication date: April 23, 2015
    Applicant: "IVIX" Ltd.
    Inventors: Nikolay Fedorovich Myasoedov, Lyudmila Alexandrovna Andreeva, Dmitriy Viktorovich Golikov
  • Patent number: 9012603
    Abstract: The invention relates to peptides which bind to human FcRn and inhibit binding of the Fc portion of an IgG to an FcRn, thereby modulating serum IgG levels. The disclosed compositions and methods may be used for example, in treating autoimmune diseases and inflammatory disorders. The invention also relates to methods of using and methods of making the peptides of the invention.
    Type: Grant
    Filed: December 18, 2009
    Date of Patent: April 21, 2015
    Assignee: Biogen Idec Hemophilia Inc.
    Inventors: Adam R. Mezo, Kevin A. McDonnell, Cristina A. Tan Hehir, Alfredo Castro
  • Publication number: 20150105335
    Abstract: The present invention provides, among other things, novel peptides and compositions for treating disease.
    Type: Application
    Filed: October 3, 2014
    Publication date: April 16, 2015
    Inventor: Richard Franklin
  • Publication number: 20150104485
    Abstract: Compounds of general formula (I): Ri—Wn—Xm-AAi-AA2-AA3-AA4-AA5-AA6-Yp—Zq—R2 (I) their stereoisomers, mixtures thereof and/or their cosmetically or pharmaceutically acceptable salts, preparation processes, cosmetic and/or pharmaceutical compositions which contain them and their use in medicine, particularly in the treatment and/or prevention of pain, inflammation, itching, pigmentation disorders and angiogenic skin disorders, and in processes of treatment and/or care of the skin and/or mucous membranes.
    Type: Application
    Filed: April 16, 2013
    Publication date: April 16, 2015
    Applicant: LUBRIZOL ADVANCED MATERIALS, INC.
    Inventors: Jose Maria Garcia Anton, Antonio Vicente Ferrer Montiel, Cristina Carreño Serraïma, Raquel Delgado González, Juan Cebrián Puche
  • Publication number: 20150098989
    Abstract: Compounds of general formula (I): R1—Wn—Xm-AA1-AA2-AA3-AA4-AA5-AA6-AA7-Yp—Zq—R2, their stereoisomers, mixtures thereof and/or their cosmetically or pharmaceutically acceptable salts, preparation processes, cosmetic or pharmaceutical compositions which contain them and their use in medicine, particularly in the treatment and/or prevention of pain, inflammation, itching, neurological, compulsive and/or neuropsychiatric diseases and/or disorders and in processes of treatment and/or care of the skin, hair and/or mucous membranes mediated by neuronal exocytosis.
    Type: Application
    Filed: April 12, 2013
    Publication date: April 9, 2015
    Inventors: Antonio Vicente Ferrer Montiel, Gregorio Fernández Ballester, José María García Antón, Cristina Carreño Serraïma, Núria Almiñana Doménech, Raquel Delgado González
  • Publication number: 20150098990
    Abstract: The present invention concerns methods and compositions that employ peptides that target dorsal root ganglion (DRG) neurons. In particular, the peptides are used to target therapeutic agents, such as proteins, liposomes, or viral particles comprising therapeutic polynucleotides, to one or more peripheral neuropathies or neuropathic pain, for example. In particular cases, the peripheral neuropathies or neuropathic pain is caused directly or indirectly by DRG neuronopathy.
    Type: Application
    Filed: October 8, 2014
    Publication date: April 9, 2015
    Inventors: Lawrence Chan, Hideto Kojima, Tomoya Terashima
  • Patent number: 8999932
    Abstract: Compounds having activity for lowering parathyroid hormone levels are described. In one embodiment, the compounds are comprised of a contiguous sequence of subunits, X1-X2-X3-X4-X5-X6-X7, wherein the X1 subunit comprises a thiol-containing moiety and the distribution of charge on the X2-X7 subunits provides the desired activity. Methods of using the compounds for treating hyperparathyroidism, bone disease and/or hypercalcemic disorders are also described, and in particular, methods for lowering plasma PTH and serum calcium are provided. The compounds can be used to treat subjects having, for example: primary, secondary or tertiary hyperparathyroidism; hypercalcemia of malignancy; metastatic bone disease; or osteoporosis.
    Type: Grant
    Filed: July 29, 2010
    Date of Patent: April 7, 2015
    Assignee: KAI Pharmaceuticals, Inc.
    Inventors: Felix Karim, Amos Baruch, Derek Maclean, Kanad Das, Qun Yin
  • Publication number: 20150093463
    Abstract: The present disclosure relates to nutritional compositions comprising a protein equivalent source, wherein 20% to 80% of the protein equivalent source includes a peptide component comprising SEQ ID NO 4, SEQ ID NO 13, SEQ ID NO 17, SEQ ID NO 21, SEQ ID NO 24, SEQ ID NO 30, SEQ ID NO 31, SEQ ID NO 32, SEQ ID NO 51, SEQ ID NO 57, SEQ ID NO 60, and SEQ ID NO 63, and 20% to 80% of the protein equivalent source comprises an intact protein, a partially hydrolyzed protein, or combinations thereof. The disclosure further relates to methods of reducing the inflammatory response and/or production of proinflammatory cytokines, i.e. Interleukin-17, by providing said nutritional compositions to a target subject.
    Type: Application
    Filed: October 14, 2014
    Publication date: April 2, 2015
    Inventors: Dirk Hondmann, Eric A.F. van Tol, Gabriele Gross, Marieke H. Schoemaker, Teartse Tim Lambers
  • Patent number: 8987191
    Abstract: Disclosed are peptide ligands for G-protein coupled receptors that are useful for treating disorders associated with G-protein coupled receptor activation.
    Type: Grant
    Filed: June 21, 2013
    Date of Patent: March 24, 2015
    Assignee: Compugen Ltd.
    Inventors: Ronen Shemesh, Zurit Levine, Amir Toporik, Chen Hermesh, Yossef Kliger, Eyal Gofer, Assaf Wool, Dvir Dahary, Yossi Cohen
  • Publication number: 20150079179
    Abstract: The invention provides sustained release formulations comprising a C5a receptor antagonist. In certain embodiments the sustained-release formulations include microparticles that comprise a complement C5aR antagonist and a biodegradable polymeric matrix. Methods of treatment comprising the sustained release formulations of the invention are also provided.
    Type: Application
    Filed: September 15, 2014
    Publication date: March 19, 2015
    Inventor: Gary P. COOK
  • Publication number: 20150065424
    Abstract: The invention relates to composition comprising a pharmaceutically effective amount of one or more functional vasoactive intestinal peptide (VIP) fragments, and the use of those compositions in the treatment of fibrosis, hypertension and other disorder.
    Type: Application
    Filed: November 17, 2014
    Publication date: March 5, 2015
    Applicant: VECTUS BIOSYSTEMS LIMITED
    Inventor: Karen Annette Duggan
  • Publication number: 20150056167
    Abstract: Human proIslet Peptides (HIP) and HIP analogs and derivatives thereof, derived from or homologous in sequence to the human REG3A protein, chromosome 2p12, are able to induce islet neogenesis from endogenous pancreatic progenitor cells. Human proIslet Peptides are used either alone or in combination with other pharmaceuticals in the treatment of type 1 and type 2 diabetes and other pathologies related to aberrant glucose, carbohydrate, andor lipid metabolism, insulin resistance, overweight, obesity, polycystic ovarian syndrome, eating disorders and the metabolic syndrome.
    Type: Application
    Filed: September 4, 2014
    Publication date: February 26, 2015
    Inventors: Claresa S. Levetan, Loraine V. Upham
  • Publication number: 20150057236
    Abstract: Sirt5, a mitochondrial Sirtuin, has been identified herein as an efficient demalonylase and desuccinylase. Disclosed herein are assays to identify Sirt5 modulators based on this robust enzymatic activity. Sirt5-specific modulators can be used study the biological function of Sirt5 and to target Sirt5 activities in treating human diseases.
    Type: Application
    Filed: July 7, 2011
    Publication date: February 26, 2015
    Applicant: CORNELL UNIVERSITY
    Inventor: Hening Lin
  • Patent number: 8962565
    Abstract: Peptide compounds of general formula (I) R1-(AA)n-X1—X2—X3-Asp-Leu-Lys-Lys-X4—X5-(AA)p-R2, cosmetic or pharmaceutical compositions comprising at least one peptide compound of general formula (I) in a physiologically acceptable medium, and methods for cosmetic treatment of skin are disclosed. The peptide compounds of general formula (I) were demonstrated to be agents making it possible to influence the pigmentation of the skin and skin appendages, by ensuring optimal transfer of the melanosomes to the keratinocytes, so as to make the skin tone uniform owing to an effect on the SCF/c-Kit signaling pathway. The compounds, compositions, and methods treat or attenuate age-related pigmentation defects and the effects of photoaging on the skin.
    Type: Grant
    Filed: January 30, 2012
    Date of Patent: February 24, 2015
    Assignee: ISP Investments Inc.
    Inventors: Claude Dal Farra, Nouha Domloge, Jean-Marie Botto
  • Patent number: 8962571
    Abstract: A method for repairing DNA damage in human keratinocytes by applying to the keratinocytes a composition comprising at least one CLOCK or PER1 gene activator and at least one DNA repair enzyme.
    Type: Grant
    Filed: April 20, 2012
    Date of Patent: February 24, 2015
    Assignee: ELC Management
    Inventors: Daniel H. Maes, Nadine A. Pernodet, Lenny Slutsky, Donald F. Collins, Kerri Goldgraben, Edward Pelle, James Timothy McCarthy
  • Publication number: 20150051159
    Abstract: New Lactococcus lactis strains, NRRL B-50571 and NRRL B-50572, and a bacterial preparation containing the same, have the ability to produce bioactive peptides that reduce blood pressure, lower LDL-cholesterol (bad cholesterol) and present antioxidant properties for better cardiovascular health. These biologically active peptides may be produced within the food for the production of a food product, such as a functional food, or they may be produced from protein sources and subsequently added to a food as part of the formulation or as part of a food supplement or a pharmaceutical preparation.
    Type: Application
    Filed: October 27, 2014
    Publication date: February 19, 2015
    Inventors: Belinda Vallejo Galland, Aarón Fernando González Córdova, Jóse Carlos Rodríguez Figueroa
  • Patent number: 8957185
    Abstract: Peptides from the MUC1 cytoplasmic domain and methods of use therefor are described. These peptides can inhibit MUC1 oligomerization, thereby preventing tumor cell growth, inducing tumor cell apoptosis and necrosis of tumor tissue in vivo.
    Type: Grant
    Filed: February 24, 2012
    Date of Patent: February 17, 2015
    Assignees: Dana-Farber Cancer Institute, Inc., Genus Oncology, LLC
    Inventors: Donald W. Kufe, Surender Kharbanda
  • Patent number: 8957013
    Abstract: The invention provides for a receptor, capable of binding to a target molecule, linked to a hygroscopic polymer or hydrogel; and the use of this receptor in a device for detecting the target molecule in a gaseous and/or liquid phase. The invention also provides for a method for detecting the presence of a target molecule in the gas phase using the device. In particular, the receptor can be a peptide capable of binding a 2,4,6-trinitrotoluene (TNT) or 2,4,-dinitrotoluene (DNT).
    Type: Grant
    Filed: October 13, 2009
    Date of Patent: February 17, 2015
    Assignee: The Regents of the University of California
    Inventors: Justyn W. Jaworski, Seung-Wuk Lee, Arunava Majumdar, Digvijay A. Raorane
  • Patent number: 8957019
    Abstract: Disclosed is an oligopeptide for treating liver fibrosis and/or hepatitis B and/or improving liver function. The oligopeptide is obtained by reflux extraction via water, ethanol precipitation and isolation through a cation exchange resin column and a gelatinous resin column from a turtle shell. Pharmaceutically conventional excipients can be added to the oligopeptide prepared according to the present invention to prepare various dosage forms. The oligopeptide has good efficacy in treating liver fibrosis and improving liver function.
    Type: Grant
    Filed: November 1, 2011
    Date of Patent: February 17, 2015
    Inventors: Haimin Lei, Qiang Li
  • Patent number: 8957032
    Abstract: Novel compounds and methods for the inhibition of biological barrier permeability and for the inhibition of peptide translocation across biological barriers are identified. Assays for determining modulators of biological barrier permeability and for peptide translocation across biological barriers are provided. Methods for treating diseases relating to aberrant biological barrier permeability and peptide translocation across biological barriers are provided. Such diseases include celiac disease, necrotizing enterocolitis, diabetes, cancer, inflammatory bowel diseases, asthma, COPD, excessive or undesirable immune response, gluten sensitivity, gluten allergy, food allergy, rheumatoid arthritis, multiple sclerosis, immune-mediated or type 1 diabetes mellitus, systemic lupus erythematosus, psoriasis, scleroderma and autoimmune thyroid diseases.
    Type: Grant
    Filed: May 6, 2009
    Date of Patent: February 17, 2015
    Assignee: Alba Therapeutics Corporation
    Inventors: Sefik Alkan, Amir Tamiz, Kelly Marie Kitchens, Malarvizhi Durai, Neil Poloso, Rosa A. Carrasco
  • Patent number: 8951963
    Abstract: The invention provides a peptide triazole conjugate and derivatives thereof, and methods of its use. The invention also provides an antibody to the peptide triazole conjugate. The invention further provides a method of identifying an HIV-1 entry inhibitor candidate.
    Type: Grant
    Filed: March 27, 2013
    Date of Patent: February 10, 2015
    Assignee: Drexel University
    Inventors: Irwin M. Chaiken, Umashankara Muddegowda, Karyn McFadden
  • Patent number: 8952128
    Abstract: The present invention relates to novel somatostatin-dopamine chimeric analogs and their therapeutic uses for the inhibition, prevention, and/or treatment of neoplasia, neuroendocrine tumors, Cushing's disease/syndrome, and other conditions.
    Type: Grant
    Filed: October 31, 2013
    Date of Patent: February 10, 2015
    Assignee: Ipsen Pharma S.A.S.
    Inventors: Zheng Xin Dong, Yeelana Shen, Sun Hyuk Kim
  • Publication number: 20150037376
    Abstract: Methods and compositions for oral administration of melanocortin receptor agonist compounds are disclosed herein. Methods and compositions for oral administration of melanocortin receptor agonist compounds are provided for treatment of sexual dysfunction, including male sexual dysfunction and female sexual dysfunction. Methods and compositions for oral administration of melanocortin receptor agonist compounds are provided for treatment of metabolic syndrome, obesity and/or diabetes. In some embodiments, a pharmaceutical composition comprising a peptide-based melanocortin receptor agonist, a protease inhibitor, an absorption enhancer is administered orally.
    Type: Application
    Filed: November 2, 2012
    Publication date: February 5, 2015
    Inventors: Gaurav Seth, Natan Bar-Chama
  • Patent number: 8946166
    Abstract: Peptides of general formula (I): R1-Wn-Xm-AA1-AA2-AA3-AA4-AA5-AA6-Yp-Zs-R2 their stereoisomers, mixtures thereof and/or their cosmetically or pharmaceutically acceptable salts, their preparation process, cosmetic or pharmaceutical compositions which contain them and their use in the treatment and/or care of conditions, disorders and/or diseases that are a consequence of muscle contraction.
    Type: Grant
    Filed: July 23, 2010
    Date of Patent: February 3, 2015
    Assignee: Lipotec, S.A.
    Inventors: Nuria Garcia Sanz, Wim Van Den Nest, Cristina Carreno Serraima, Antonio Ferrer Montiel, Juan Cebrian Puche, Nuria Alminana Domenech, Gregorio Fernandez Ballester
  • Publication number: 20150031634
    Abstract: The present invention provides, among other things, methods of treating Marfan Syndrome and/or a Marfan-related disorder including administering to a subject suffering from or susceptible to Marfan Syndrome and/or a Marfan-related disorder an angiotensin (1-7) peptide. In some embodiments, the angiotensin (1-7) peptide is administered at an effective dose periodically at an administration interval such that at least one symptom or feature of Marfan Syndrome and/or a Marfan-related disorder is reduced in intensity, severity, duration, or frequency or has delayed in onset.
    Type: Application
    Filed: October 3, 2014
    Publication date: January 29, 2015
    Inventor: Richard Franklin
  • Publication number: 20150017097
    Abstract: The invention features sincalide formulations that include an effective amount of sincalide, a bulking agent/tonicity adjuster, a stabilizer, a surfactant, a chelator, and a buffer. The invention also features kits and methods for preparing improved sincalide formulations as well as methods for treating, preventing, and diagnosing gall bladder-related disorders using sincalide formulations.
    Type: Application
    Filed: October 2, 2014
    Publication date: January 15, 2015
    Applicant: BRACCO DIAGNOSTICS INC.
    Inventors: Edmund C. METCALFE, Jo Anna MONTEFERRANTE, Margaret NEWBORN, Irene KUCHAREWICZ ROPIAK, Ernst SCHRAMM, Gregory W. WHITE, Julius P. ZODDA
  • Patent number: 8933194
    Abstract: Melanocortin receptor-specific linear peptides of the formula where R1, R2, R3, R4, R5, R6, R7, R8, R9 and R10 are as defined in the specification, compositions and formulations including peptides of the foregoing formula or salts thereof, and pharmaceutical compositions for preventing, ameliorating or treating melanocortin-1 receptor-mediated or responsive diseases, indications, conditions and syndromes.
    Type: Grant
    Filed: May 16, 2012
    Date of Patent: January 13, 2015
    Assignee: Palatin Technologies, Inc.
    Inventors: Wei Yang, Yi-Qun Shi
  • Patent number: 8933031
    Abstract: Provided is a low molecular polypeptide that can inhibit angiogenesis consisting of amino acid sequence YRGKKA, which is same to one portion sequence in apolipoprotein (a) Kringle V. Also provided are pharmaceutical composition and the uses for preventing or treating diseases relating to angiogenesis.
    Type: Grant
    Filed: February 4, 2008
    Date of Patent: January 13, 2015
    Assignee: Shanghai First People's Hospital
    Inventors: Hui Zhao, Xun Xu